Abstract: Pharmaceutical compositions that include inhibitors of mitochondrial fission are described for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcohol-related liver disease.

Abstract: Pharmaceutical compositions that include inhibitors of mitochondrial fission are described for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcohol-related liver disease.

Abstract: Methods and apparatus of some aspects of the invention relate to the synthesis of high fidelity polynucleotides. In particular, aspects of the invention relate to concurrent enzymatic removal of amplification sequences and ligation of processed oligonucleotides into nucleic acid assemblies. According to some embodiments, the invention provides a method for producing a target nucleic acid having a predefined sequence. In some embodiments, the method comprises the step of providing a plurality of oligonucleotides, wherein each oligonucleotides comprises (i) an internal sequence identical to a different portion of a sequence of a target nucleic acid, (ii) a 5? sequence flanking the 5? end of the internal sequence and a 3? flanking sequence flanking the 3? end of the internal sequence, each of the flanking sequence comprising a primer recognition site for a primer pair and a restriction enzyme recognition site.

Abstract: Methods and apparatus of some aspects of the invention relate to the synthesis of high fidelity polynucleotides. In particular, aspects of the invention relate to concurrent enzymatic removal of amplification sequences and ligation of processed oligonucleotides into nucleic acid assemblies. According to some embodiments, the invention provides a method for producing a target nucleic acid having a predefined sequence. In some embodiments, the method comprises the step of providing a plurality of oligonucleotides, wherein each oligonucleotides comprises (i) an internal sequence identical to a different portion of a sequence of a target nucleic acid, (ii) a 5? sequence flanking the 5? end of the internal sequence and a 3? flanking sequence flanking the 3? end of the internal sequence, each of the flanking sequence comprising a primer recognition site for a primer pair and a restriction enzyme recognition site.

Abstract: Pharmaceutical compositions that include inhibitors of mitochondrial fission are described for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcohol-related liver disease.

Abstract: Methods and apparatus of some aspects of the invention relate to the synthesis of high fidelity polynucleotides. In particular, aspects of the invention relate to concurrent enzymatic removal of amplification sequences and ligation of processed oligonucleotides into nucleic acid assemblies. According to some embodiments, the invention provides a method for producing a target nucleic acid having a predefined sequence. In some embodiments, the method comprises the step of providing a plurality of oligonucleotides, wherein each oligonucleotides comprises (i) an internal sequence identical to a different portion of a sequence of a target nucleic acid, (ii) a 5? sequence flanking the 5? end of the internal sequence and a 3? flanking sequence flanking the 3? end of the internal sequence, each of the flanking sequence comprising a primer recognition site for a primer pair and a restriction enzyme recognition site.

Abstract: Methods and apparatus of some aspects of the invention relate to the synthesis of high fidelity polynucleotides. In particular, aspects of the invention relate to concurrent enzymatic removal of amplification sequences and ligation of processed oligonucleotides into nucleic acid assemblies. According to some embodiments, the invention provides a method for producing a target nucleic acid having a predefined sequence. In some embodiments, the method comprises the step of providing a plurality of oligonucleotides, wherein each oligonucleotides comprises (i) an internal sequence identical to a different portion of a sequence of a target nucleic acid, (ii) a 5? sequence flanking the 5? end of the internal sequence and a 3? flanking sequence flanking the 3? end of the internal sequence, each of the flanking sequence comprising a primer recognition site for a primer pair and a restriction enzyme recognition site.

Abstract: This invention concerns apparatus and a method for authenticating a subject using their eye as an identifying biometric, in particular the shape of their cornea. The apparatus comprises an image projection device to generate and project an image of a pattern, made up of plural discrete points, onto at least a part of the cornea of an eye of the person. An image capture device to capture an image of the pattern of plural discrete points, after reflection in at least a part of the cornea of an eye of the person. And, a computer processor to extract a data set defining the locations of the discrete points in the captured image. The method comprises capturing an image of an illuminated pattern, made up of plural discrete points, after reflection in at least a part of the cornea of an eye of the subject. Comparing the locations of the discrete points in the pattern of the captured image against the locations of the discrete points in the pattern of a reference image.

Abstract: The invention relates to the use of dichloroacetate and chemical equivalents thereof for the treatment of cancer by inducing apoptosis or reversing apoptosis-resistance in a cell Preferably, the dosage is 10-100 mg/kg Preferably, sodium dichloroacetate is used. The dichloroacetate may optionally be given in combination with a pro-apoptotic agent and/or a chemotherapeutic agent Preferably, the cancers treated are non-small cell lung cancer, glioblastoma and breast carcinoma.

Abstract: A T-ball training system helps batters develop focus during ball hitting as well as timing skills and uses a tee that shines a light out of the top of the tee. A ball has a light tunnel therein that has a 90-degree bend, so that when the light shines out of the top, the light enters the tunnel at one end and is issued out of the other end, visible to the batter. The light is activated for a certain time interval such that the batter is expected to hit the ball whenever the light is on. The control system of the light can be either directly on the tee or can be assisted by a wireless transmitter. A second light can be provided that also issues light out of the top of the tee, this second light issuing a different color than the first and being on whenever the first light is off and being off whenever the first light is on.

Abstract: This invention concerns apparatus and a method for authenticating a subject using their eye as an identifying biometric, in particular the shape of their cornea. The apparatus comprises an image projection device to generate and project an image of a pattern, made up of plural discrete points, onto at least a part of the cornea of an eye of the person. An image capture device to capture an image of the pattern of plural discrete points, after reflection in at least a part of the cornea of an eye of the person. And, a computer processor to extract a data set defining the locations of the discrete points in the captured image. The method comprises capturing an image of an illuminated pattern, made up of plural discrete points, after reflection in at least a part of the cornea of an eye of the subject. Comparing the locations of the discrete points in the pattern of the captured image against the locations of the discrete points in the pattern of a reference image.

Abstract: The invention relates to the use of dichloroacetate and chemical equivalents thereof for the treatment of cancer by inducing apoptosis or reversing apoptosis-resistance in a cell Preferably, the dosage is 10-100 mg/kg Preferably, sodium dichloroacetate is used. The dichloroacetate may optionally be given in combination with a pro-apoptotic agent and/or a chemotherapeutic agent Preferably, the cancers treated are non-small cell lung cancer, glioblastoma and breast carcinoma.

Abstract: The rivet comprises a tubular body 12 having a shank 14 having a rivet head at one end and an end portion 32 of which is tapered externally and internally towards the other (tail) end 20. A stem 10, disposed in the bore 18 of the body, has a stem-tail 22 which projects from the head end and breaks off when the rivet is set, a plug 24 in the bore 18, and a terminal head 28 abutting the tail-end 20. The diameter of the plug is reduced progressively and stepwise towards the terminal head, providing an abutment 50 and an annular groove 29 between the terminal head 28 and the abutment 50. Material of the end portion 20 extends into the groove to maintain the body and stem assembled, and enters further into the groove during setting of the rivet.The rivet is set by pulling the stem tail while supporting the body, causing the shank to collapse into a bulge which provides a blind head.The external tapering of the portion 32 promotes bulging at a lower applied force than would otherwise be required.